Tirzepatide

Buy Tirzepatide Peptide | Proven Dual GIP/GLP-1 Receptor Agonist for Metabolic Research | PrimaLab Peptide

Tirzepatide is a synthetic dual agonist research peptide simultaneously targeting two metabolic receptors: the GIP receptor (glucose-dependent insulinotropic polypeptide receptor) and the GLP-1 receptor (glucagon-like peptide-1 receptor). Researchers who buy Tirzepatide peptide use it to investigate dual receptor co-activation pharmacology, the relative contributions of GIP receptor vs. GLP-1R to metabolic outcomes, glucose-dependent insulin secretion through two independent incretin pathways, GIP receptor biology, appetite and satiety signalling through dual incretin pathways, and systematic comparison with single-receptor GLP-1R agonists such as Semaglutide and with triple receptor agonists such as Retatrutide. PrimaLab Peptide supplies research-grade Tirzepatide at ≥99.36% purity, independently verified by Janoshik Analytical via HPLC and mass spectrometry, with a full batch-specific Certificate of Analysis included with every order.

What Is Tirzepatide?

Tirzepatide is a 39-amino acid synthetic peptide dual agonist of the GIP receptor and GLP-1 receptor, with a C18 fatty acid chain enabling albumin binding for extended half-life. Its molecular weight is approximately 4813.5 Da (molecular formula C₂₂₅H₃₄₈N₄₈O₆₈).

Key structural features relevant to research:

• Dual receptor pharmacology: Tirzepatide activates both GIP receptor and GLP-1R — two GPCRs with overlapping but distinct expression patterns, signalling mechanisms, and physiological roles in glucose homeostasis, appetite regulation, and metabolic adaptation. This dual agonism is the central pharmacological characteristic distinguishing Tirzepatide from single-receptor GLP-1R agonists like Semaglutide
• Aib at position 2: Like Semaglutide, Tirzepatide incorporates Aib (alpha-aminoisobutyric acid) at position 2 for DPP-IV resistance
• C18 fatty acid acylation: A C18 fatty acid chain is attached enabling albumin binding for extended half-life — essential for research protocols requiring prolonged sustained dual receptor activation without repeated peptide addition
• GIP-optimised sequence: Tirzepatide’s 39-amino acid sequence is based on the GIP peptide backbone (rather than the GLP-1 backbone used by Semaglutide), with modifications optimising dual GIP/GLP-1R activity

A comprehensive overview of GIP receptor biology and incretin pharmacology relevant to Tirzepatide research is available through published PubMed research on Tirzepatide and the NIH-archived review of dual incretin receptor agonism.

Tirzepatide Research Applications

Tirzepatide occupies a distinct position in metabolic research — as the only dual GIP/GLP-1R agonist in PrimaLab Peptide’s catalog, it provides a unique pharmacological tool for studying the specific contribution of GIP receptor engagement to metabolic outcomes above and beyond GLP-1R agonism alone:

• GIP receptor biology research: Tirzepatide is the primary tool for studying GIP receptor pharmacology in the context of concurrent GLP-1R co-activation. Research examines GIP receptor-mediated insulin secretion, GIP receptor signalling cascades (Gs-cAMP, Gq-IP3/DAG), and GIP receptor expression in pancreatic, adipose, and CNS tissue research contexts
• Incretin synergy research: A central research question with Tirzepatide is whether GIP and GLP-1 receptor co-activation produces additive or synergistic effects on insulin secretion, appetite suppression, and metabolic outcomes compared to single-receptor activation. Research designs comparing Tirzepatide against Semaglutide (GLP-1R only) allow systematic investigation of GIP receptor’s incremental contribution
• Glucose-dependent insulin secretion research: Both GIP receptor and GLP-1R stimulate insulin secretion in a glucose-dependent manner, but through partially distinct intracellular signalling pathways. Research examines the combined downstream effects on beta cell cAMP production, calcium mobilisation, and insulin exocytosis
• Adipose tissue metabolism research: GIP receptors are expressed in adipose tissue — an expression pattern distinct from GLP-1R distribution. Research has examined Tirzepatide’s effects on adipocyte biology, fat storage, and lipolytic mechanisms through GIP receptor pathways not engaged by pure GLP-1R agonists
• Central appetite pathway research: Both GIP receptor and GLP-1R are expressed in hypothalamic and brainstem appetite-regulatory circuits. Research examines Tirzepatide’s central effects on satiety and food intake through dual central receptor activation
• Multi-receptor agonist comparative research: Tirzepatide is a key comparator in systematic multi-receptor agonist research alongside Semaglutide (GLP-1R only), Mazdutide (GLP-1R/GCGR), and Retatrutide (GLP-1R/GIP/GCGR triple) — allowing dissection of individual and combined receptor pathway contributions to metabolic outcomes

Purity & Third-Party Testing

Every batch of Tirzepatide supplied by PrimaLab Peptide is independently tested by Janoshik Analytical:

• HPLC — quantitative purity confirmed at ≥99.36%
• Mass Spectrometry — molecular identity and MW verification (~4813.5 Da), confirming both the 39-amino acid sequence and the C18 fatty acid acylation

The COA is published openly — not just available on request. The batch-specific report is tied to your specific lot. You can verify the data yourself before ordering. Purity alone isn’t enough — sequence verification by mass spec confirms you have the correct dual agonist compound, not a related but distinct peptide analogue.

Storage & Reconstitution

• Lyophilized (sealed): Store at −20°C, away from light. Keep vials sealed until research use begins
• After reconstitution: Store at 2–8°C. Use promptly — avoid storing at room temperature
• Reconstitution: Use sterile Bacteriostatic Water (BAC Water). The C18 acylation may slow dissolution — add solvent slowly down the inside vial wall and allow adequate time for complete dissolution. Swirl gently — do not shake or vortex
• Freeze-thaw cycles: Avoid. Aliquot before freezing if your protocol requires multiple experiments
• Working environment: Standard sterile lab technique applies throughout reconstitution and handling

Product Specifications

Name	Tirzepatide
Mechanism	Dual GIP receptor + GLP-1 receptor agonist
Molecular Formula	C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight	~4813.5 Da
Length	39 amino acids
Purity	≥99.36% (Janoshik HPLC + Mass Spectrometry verified)
Form	Lyophilized powder
Available Sizes	5mg, 10mg
Storage (lyophilized)	−20°C, away from light
Storage (reconstituted)	2–8°C, use promptly
Reconstitution	Bacteriostatic Water (BAC Water)
Testing Lab	Janoshik Analytical (independent third-party)
COA	Batch-specific — publicly posted, included with every order
Intended Use	In vitro and laboratory research only

Frequently Asked Questions — Tirzepatide Peptide

What is Tirzepatide used for in research?

Researchers who buy Tirzepatide peptide use it to investigate dual GIP/GLP-1R co-activation pharmacology, GIP receptor biology in the context of concurrent GLP-1R activation, incretin synergy mechanisms, glucose-dependent insulin secretion through two independent pathways, adipose tissue metabolism through GIP receptor pathways, central appetite pathway research, and systematic comparison with Semaglutide (GLP-1R only) and Retatrutide (triple agonist) to dissect individual receptor contributions to metabolic outcomes. Published research is available on PubMed.

What makes Tirzepatide different from Semaglutide in research?

The fundamental pharmacological difference is receptor targeting. Semaglutide is a single GLP-1R agonist — it activates only GLP-1 receptors. Tirzepatide is a dual agonist activating both GIP receptor and GLP-1R simultaneously. This makes Semaglutide the essential GLP-1R-only reference comparator: comparing Semaglutide and Tirzepatide directly in research allows systematic identification of what GIP receptor engagement adds to GLP-1R agonism. Additionally, Tirzepatide’s sequence is based on the GIP peptide backbone rather than the GLP-1 backbone used by Semaglutide, producing distinct receptor binding characteristics at each receptor.

Is Tirzepatide from PrimaLab Peptide independently tested?

Yes. Every batch is independently verified by Janoshik Analytical at ≥99.36% purity via HPLC and mass spectrometry identity confirmation (~4813.5 Da). The COA is published openly per batch — researchers can verify the data before or after ordering. The batch number on your vial links to the specific Janoshik test report.

What is the significance of Tirzepatide’s C18 fatty acid chain for research?

The C18 fatty acid acylation on Tirzepatide enables albumin binding in physiological conditions — extending its effective half-life to approximately one week in vivo, similar to Semaglutide. For in vitro research, this extended stability means sustained dual GIP/GLP-1R activation in cell culture systems without frequent peptide replenishment — practically important for multi-day receptor signalling studies. The acylation may also slightly slow initial dissolution during reconstitution — allow adequate time for complete dissolution in BAC Water.

How does Tirzepatide compare to Retatrutide in research design?

Retatrutide is a triple receptor agonist targeting GLP-1R + GIP receptor + GCGR (glucagon receptor) simultaneously. Tirzepatide targets only GLP-1R + GIP receptor (dual agonist), without glucagon receptor engagement. This makes Tirzepatide the appropriate comparator for studies isolating the GIP/GLP-1R dual agonism component from the full triple agonist profile of Retatrutide — allowing systematic dissection of what glucagon receptor engagement adds to the dual GIP/GLP-1R pharmacology.

What metabolic peptides are commonly studied alongside Tirzepatide?

Researchers buying Tirzepatide peptide for metabolic research frequently explore the complete GLP-1 class catalog at PrimaLab Peptide for systematic comparative studies: Semaglutide (GLP-1R reference), Mazdutide (GLP-1R/GCGR dual agonist), Retatrutide (triple agonist), and Cagri+Sema Blend (amylin/GLP-1R pathway). Browse the complete Metabolic Peptides category.

Related Research Peptides

Researchers buying Tirzepatide peptide for GIP/GLP-1 and metabolic research frequently explore:

• Semaglutide — single GLP-1R agonist reference comparator
• Retatrutide — triple GLP-1R/GIP/GCGR agonist for comprehensive multi-receptor research
• Mazdutide — dual GLP-1R/GCGR agonist for comparative dual receptor research
• Cagrilitide — amylin analogue for amylin/GLP-1R dual pathway research
• Cagri+Sema Blend — Cagrilitide + Semaglutide dual amylin/GLP-1R research stack
• AOD9604 — modified GH fragment for complementary fat metabolism research

Browse our complete Metabolic Peptides category. Bulk researchers can apply for discounted rates through our Wholesale Portal. Reconstitute with BAC Water, available in our Accessories & Reconstitution Supplies section.

⚠️ For in-vitro and laboratory research use only. Not for human or veterinary use. Not a drug, supplement, or medical treatment. No filler, no hype — documented, traceable peptides for serious research. Researchers are solely responsible for compliance with all applicable regulations.